Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis
Sanjay Bandyopadhyay, Saibal Das, Shambo Samrat Samajdar, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 10, pp. 102849-102849
Closed Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes
Lindsey Wang, Nathan A. Berger, David C. Kaelber, et al.
Gastroenterology (2024) Vol. 167, Iss. 4, pp. 689-703
Open Access | Times Cited: 40
How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Ralf Weiskirchen, Amedeo Lonardo
British Journal of Pharmacology (2025)
Open Access | Times Cited: 3
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group
Andrej Janež, Emir Muzurović, Paweł Bogdański, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 9, pp. 1865-1892
Open Access | Times Cited: 15
2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes
Amélio F. Godoy‐Matos, Cynthia Melissa Valério, Wellington S. Silva Júnior, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 12
The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases
Meng Li, Man Cui, Guoxia Li, et al.
Hormone and Metabolic Research (2024) Vol. 56, Iss. 10, pp. 683-696
Closed Access | Times Cited: 11
A System-Based Review on Effects of Glucagon-Like Peptide-1 Receptor Agonists: Benefits vs Risks
Leandro Fadel, Gigi Thao, Tanvi Chitre, et al.
Cureus (2025)
Open Access | Times Cited: 1
Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
Jeysson E. Mejía-Guzmán, Ramón A. Belmont-Hernández, Norberto C. Chávez‐Tapia, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 2959-2959
Open Access | Times Cited: 1
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Ilaria Milani, Marianna Chinucci, Frida Leonetti, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 855-855
Open Access | Times Cited: 1
From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention
Benedetta Maria Motta, Mario Masarone, Pietro Torre, et al.
Cancers (2023) Vol. 15, Iss. 22, pp. 5458-5458
Open Access | Times Cited: 19
Intrapatient Changes in CT-Based Body Composition After Initiation of Semaglutide (Glucagon-Like Peptide-1 Agonist) Therapy
Leslie W. Nelson, Matthew H. Lee, John W. Garrett, et al.
American Journal of Roentgenology (2024) Vol. 223, Iss. 6
Closed Access | Times Cited: 8
Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities
Riccardo Sarzani, Matteo Landolfo, Chiara Di Pentima, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 6
Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study
Chia-Chih Kuo, Min‐Hsiang Chuang, Chun‐Hsien Li, et al.
Hepatology International (2024)
Closed Access | Times Cited: 4
Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder
Mette Kruse Klausen, Gitte M. Knudsen, Tina Vilsbøll, et al.
Basic & Clinical Pharmacology & Toxicology (2025) Vol. 136, Iss. 3
Open Access
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
Klaudia Nowak, Krzysztof Łupina, Anna Romac, et al.
Annals of Pharmacotherapy (2025)
Closed Access
Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
Weijun Gu, Yibing Lu, Xinhua Ye, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease
В. Т. Ивашкин, О. М. Драпкина, M. V. Maevskaya, et al.
Russian Journal of Gastroenterology Hepatology Coloproctology (2025) Vol. 35, Iss. 1, pp. 94-152
Open Access
Efficacy of Hypoglycemic Agents in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Systematic Review and Network Meta‐Analysis
Qiao Ren, Yao Tan, Guixiang Zhang, et al.
Journal of Evidence-Based Medicine (2025) Vol. 18, Iss. 2
Closed Access
Lipid Microparticle‐Based Phantoms Modeling Hepatic Steatosis for the Validation of Quantitative Imaging Techniques
Connor Endsley, Shariq Ali, Karim Salhadar, et al.
Small Methods (2025)
Open Access
3,3′-Diindolylmethane Ameliorates Metabolism Dysfunction-Associated Fatty Liver Disease via AhR/p38 MAPK Signaling
Jiewen Su, Heng Fang, Yunfeng Lin, et al.
Nutrients (2025) Vol. 17, Iss. 10, pp. 1681-1681
Open Access
Diversity of pleiotropic effects of semaglutide: From potential mechanisms to real clinical outcomes
T. Yu. Demidova, M. Ya. Izmaylova, M. E. Shirnina
FOCUS Endocrinology (2025) Vol. 6, Iss. 1, pp. 20-30
Closed Access
From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors and Prevention
Benedetta Maria Motta, Mario Masarone, Pietro Torre, et al.
(2023)
Open Access | Times Cited: 9
The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide
Marcelo Maia Pinheiro, Luciana Gasques de Souza, Guilherme Pavini Nunes, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 9, pp. 1525-1531
Closed Access | Times Cited: 3
Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review
Sultan A. Alfawaz, Abdulhadi S. Burzangi, Ahmed Esmat
Cureus (2024)
Open Access | Times Cited: 3
Potential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow?
Evanthia Gouveri, Djordje S. Popovic, Νικόλαος Παπάνας
Diabetes Therapy (2023) Vol. 15, Iss. 1, pp. 13-18
Open Access | Times Cited: 7
Response to semaglutide of non-drinker subjects with type 2 diabetes
Giovanni Petralli, Francesco Raggi, Alice Del Zoppo, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top